Management ChangeJun 4, 2026, 07:36 AM
BeyondSpring Appoints New CEO, CFO; Founder Huang Transitions to Chair
AI Summary
BeyondSpring Inc. announced significant leadership transitions, effective July 1, 2026, to deliver focused execution on its DUBLIN-4 confirmatory Phase 3 program for Plinabulin. Dr. Lan Huang will transition from her role as CEO to Chair of the Board, forfeiting unvested equity, to dedicate her executive focus to SEED Therapeutics. Min Qiu is appointed Chief Executive Officer and Na Li as Chief Financial Officer, while Dr. Jiangwen Majeti is named Vice Chair of the Board, receiving a grant of 100,000 share options.
Key Highlights
- Dr. Lan Huang transitions from CEO to Chair of the Board, effective July 1, 2026.
- Dr. Huang forfeits all unvested equity and long-term incentive awards.
- Min Qiu (43) appointed Chief Executive Officer, effective July 1, 2026.
- Na Li (49) appointed Chief Financial Officer, effective July 1, 2026.
- Dr. Jiangwen Majeti appointed Vice Chair of the Board, effective July 1, 2026.
- Dr. Majeti receives a one-time grant of options for 100,000 shares, vesting over four years.
- Leadership changes aim to focus on DUBLIN-4, a 442-patient confirmatory Phase 3 trial for Plinabulin.
- Plinabulin's U.S. composition-of-matter protection extends through 2036, potentially 2041.
Price Impact
More from BYSI